System is a
The Sarah Nanotechnology System is a novel solution designed to treat metastatic solid tumors through the delivery of thermal energy to malignant cells, thereby causing cancer cell death via hyperthermia.
New Phase’s Sarah Nanotechnology is comprised of proprietary nanoparticles that are intravenously administered to the patient, followed by exposure to an alternating magnetic field (AMF) system, developed by New Phase. After accumulation of the nanoparticles at the tumour site, the patient is exposed to a low frequency non-ionizing AMF that activates the nanoparticles in a controlled manner, causing the cancer cells to heat up and die, without causing damage to the surrounding healthy tissue.
New Phase was founded in 2013 by Ofer Shalev, MBA and Dr. Rafi Hof, PhD Engineering, and has developed into a leading medical device company.
New Phase captures expertise and knowledge within the field of magnetic fluid hyperthermia.
New Phase also specializes in the production and characterization of
magnetic nanomaterials suitable for delivery of magnetic hyperthermia.
The Company is equipped with a fully operating state of the art clean room for the production of nanoparticles.
New Phase employs a highly specialized team of experts with advanced degrees in Biology, Chemistry, Engineering, and Physics.
New Phase is expected to initiate a First-in-Human clinical trial in Q3 2021.
New Phase was founded in 2013 by Mr. Ofer Shalev, MBA, and Dr. Rafi Hof, PhD, Eng.
Both founders have cooperated in the past in the management of a previous medical company – Redent Nova Ltd.
Ofer Shalev, CEO of New Phase has vast experience in fund raising, creating companies from innovative ideas to implementation of operational stages.
Dr. Rafi Hof has broad experience in multi-disciplinary sciences and engineering in the medical device field, including analytical, optical and mechanical design.
Scientific Advisory Board
Prof. Dan Peer
Prof. Dan Peer is the director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is also the Vice President for Research & Development at TAU. From 2016-2020, he was the Chair of TAU Cancer Biology Research Center; the biggest Cancer Center in Israel that includes 17 affiliated hospitals and from 2017 he is the Founding and Managing Director of SPARK Tel Aviv, Center for Translational Medicine at TAU and lately was elected to the US National Academy of Engineering (NAE), part of three US National Academies: science, engineering and medicine.
Prof. Peer has more than 120 pending and granted patents. Some of them have been licensed to several pharmaceutical companies and one is currently under registration (as a new drug in inflammatory bowel disease). In addition, based on his work, five spin-off companies were generated aiming to bring innovative personalized molecular medicines into clinical practice using nanotechnology.
Prof. Peer is a scientific advisory board member in more than 15 companies and 20 scientific journals. He is a past president of the Israeli chapter of the Controlled Release Society, and a past member of the board of the Israel Young Academy of Science.
Prof. Peer is also the Chairman of the board of directors of Ramot Ltd. and of TAU Ventures.
Dr. Glenwood Goss
Dr. Glenwood Goss is the chair of the Thoracic Oncology Site Committee NCIC CTG, a Professor of medicine at the University of Ottawa, and director of Clinical and Translational Research at the Ottawa Hospital Cancer Centre. He was the previous Division Head of Medical Oncology and the head of the Phase I Program at the Ottawa Hospital Cancer Centre, University of Ottawa. He is a clinical investigator in the Ottawa Hospital Research Institute and the chair of the Clinical Research Executive Committee at the Ottawa Hospital Cancer Centre.
For the past 8 years he has served on the IND Executive, NCIC CTG. Dr. Goss is on the editorial board of a number of peer reviewed journals including the Journal of Clinical Oncology, the Journal of Clinical Lung Cancer, and he chairs the Publications Committee of the International Association for the study of lung cancer.
His areas of interest are early cancer drug development and thoracic oncology. He has participated in the early development of the EGFR inhibitor gefitinib, and a number of VEGFR inhibitors including AZD2171, ABT869, brivanib and sutent. Dr. Goss has been the principal investigator on a number of Phase III trials including the adjuvant North American Intergroup Trial CTSU BR.19 in non-small-cell-lung cancer. He is an investigator on a number of ongoing Phase I/II trials which include an anti TWEAK antibody, a Hedgehog inhibitor, and a Notch inhibitor among others and currently chairs two large international randomized studies.
Dr. Goss has been the recipient of multiple peer-reviewed and industry research grants. He collaborates closely with four senior scientists in the areas of EGFR, DNA repair, angiogenesis and oncolytic viruses and they have a number of ongoing translational research and biomarker projects.
Dr. Arnoldo Cyjon
- Dr. Arnold Cyjon is the former Deputy Head of the Department of Oncology at the Shamir Medical Center, Zerifim, Israel and till 2021 he was in charge of the Thoracic Oncology section. He graduated medical school in 1978, has a degree in medical oncology and radiotherapy (1988), and is an expert in lung cancer and invasive oncology. He was a staff oncologist at the Department of Oncology at the Rabin Medical Center, Israel, and till 2001 he was in charge of the Thoracic Oncology Unit and the Invasive Oncology Center.
Prof. Zeev Rotstein, MD, MHA
Prof. Rotstein is an Health Systems Management & Hospital Planning and Construction Expert, Physician (MD with specialization in Cardiology) and health management executive (MHA) with extensive medical operations management experience within complex healthcare systems and wide-ranging international experience in hospital planning, developing and construction.
Prof. Rotstein is a seasoned healthcare executive who has the ability to balance strategic decisions and financial discipline with expertise in organizational planning, multimillion-dollar capital projects, contract negotiations, and team development. He brings to the international healthcare arena a combination of healthcare management and consultancy experience, academic excellence, and care as a physician.
Prof. Rotstein graduated from the Sackler School of Medicine at Tel Aviv University where he continued on to do his internship and residency in the Chaim Sheba Medical Heart Institute. He received his Masters of Health Administration (MHA) from the Leon Recanti Graduate School of Business Administration at Tel Aviv University and was certified by the Israel Ministry of Health as a specialist in Health Systems Management. He held fellowships at the New York Department of Health, Tufts University and Johns Hopkins Medical Center School of Hygiene and Public Health.
Prof. Rotstein joined the Hadassah Medical Organization as Director General (2016 – 2021) after a long and distinguished career at the Chaim Sheba Medical Center at Tel Hashomer, where he began as a senior cardiologist in 1977 and served as its Director General from 2004-2016.
Prof. Rotstein taught at Bar Ilan University, Tel Aviv University and The Academic Center for Law and Science. He is an Associate Clinical Professor who has published more than 100 articles in peer-reviewed journals. His membership in numerous professional societies and organizations includes the Israel Medical Association, Israel Heart Society, European Heart Society and the Israel Association of Hospital Managers.
Board of Director Membership Highlights
Public Director, Netto Melinda
Board of Directors, Raphael Advanced Defense Systems, Ltd.
Non-Executive Director, G Medical Innovations